Congruence Therapeutics: An Entrepreneur’s and an Investor’s Perspectives on Funding
On December 9, 2026, the CQIB welcomes you to the Holiday Inn Laval for the 5th edition of the Life Sciences Financing Forum. This event will once again bring together the people who shape the financing of health innovation, in Quebec and across Canada.
Panel 3: Local Roots, Global Ambition: The Congruence Therapeutics Story
The day’s third panel will focus on the journey of Congruence Therapeutics .
Moderated by Jeremy Sculnick, Partner at Stikeman Elliott S.E.N.C.R.L., s.r.l., the discussion will highlight the path of this Quebec company, which is developing drugs that target certain genetic diseases at their source.
Charles Grubsztajn, Chief Operating Officer, will present the key stages of the company’s financing, from idea to investment. Maxime Daigle, CPA, Investment Director at Investissement Québec, will share his perspective as an investor active in venture capital for biotechnology and medical technologies.
Meet the Moderator
Jeremy Sculnick is a Partner at Stikeman Elliott S.E.N.C.R.L., s.r.l.. He advises clients on Canadian and cross-border mergers and acquisitions, private equity, corporate finance and venture capital transactions, with a particular focus on life sciences and technology.
He co-leads the firm’s Life Sciences and Health Care practice. He works with public and private companies, both Canadian and multinational, as well as investors, across a wide range of sectors, particularly life sciences and technology.
Mr. Sculnick also has extensive experience in venture capital financings, strategic investments, public company matters and corporate governance.
Meet Our Panelists
At 4 p.m., the Forum will close with a presentation by Charles Grubsztajn, Chief Operating Officer of Congruence Therapeutics. Founded in Montréal in 2021, Congruence Therapeutics develops drugs that treat certain genetic diseases at their source, and has already reached human clinical trials.
The company’s funding journey illustrates the Forum’s theme well. Since 2021, Congruence has raised $139.5 million from leading investors, including OrbiMed, Dimension, Amplitude, the Fonds de solidarité FTQ, Lumira, Investissement Québec and BDC. It is also continuing its research collaborations, notably an expanded partnership with Ono Pharmaceutical.
Mr. Grubsztajn brings more than twenty years of experience in business development and biotechnology management. Among other roles, he served as President and CEO of MethylGene, which became Mirati Therapeutics, then as Chief Operating Officer of Neopharm Labs before joining Congruence. He holds a Bachelor of Civil Law and an MBA from McGill University.
Maxime Daigle, CPA, Investment Director at Investissement Québec, will share his insights on financing companies in the sector. He specializes in venture capital for biotechnology and medical technologies, and understands the financing challenges companies face at every stage of their growth. He cut his teeth over ten years at PwC, where he advised dozens of clients on mergers and acquisitions and led due diligence on transactions ranging from several million to several billion dollars. He then served as Corporate Controller of a major Canadian public company before joining Investissement Québec in 2023. He also sits as a board observer for several biotechnology companies, giving him a concrete view of both sides of the table: that of investors and that of entrepreneurs.
Entrepreneurs, investors and industry professionals: this discussion will offer insight into investment trends and into what investors expect from the companies they support.
It will also be a prime opportunity to connect with these experts and build strategic relationships at the heart of the life sciences ecosystem.






Comments